Moving toward safer AAV manufacturing: Evaluation of synthetic DNA as an alternative to plasmid DNA
As AAV-based gene therapies move toward broader clinical adoption, the safety of viral vector manufacturing has come under increasing focus. Growing evidence of plasmid-derived DNA impurities in rAAV products, combined with heightened regulatory expectations around product quality and patient safety, is driving the industry to re-evaluate traditional plasmid DNA-based manufacturing approaches.
This whitepaper explores the limitations of plasmid DNA as a starting material for AAV manufacturing and examines the need for safer, more controlled alternatives. Learn how advances in synthetic DNA technologies are enabling the production of high-quality AAV vectors while reducing the risks associated with bacterial-derived impurities, supporting the development of safer and more consistent gene therapies.
Discover more technical insights:
